<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01213979</url>
  </required_header>
  <id_info>
    <org_study_id>P-Monofer-PK-CIA-04</org_study_id>
    <nct_id>NCT01213979</nct_id>
  </id_info>
  <brief_title>Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)</brief_title>
  <acronym>PK-CIA-04</acronym>
  <official_title>Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)(PK-CIA-04)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacosmos A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacosmos A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmakokinetic properties of higher doses (500 mg&#xD;
      and 1000 mg) of Monofer(R)in patients suffering from non-hematological malignancies with&#xD;
      Chemotherapy induced anaemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total serum iron pharmakokinetic parameters</measure>
    <time_frame>24, 48 and 72 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Non-hematological Malignancies</condition>
  <arm_group>
    <arm_group_label>1000 mg iron isomaltoside 1000 as intravenous infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>500 mg iron isomaltoside 1000 as bolus injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>500 mg iron isomaltoside 1000</intervention_name>
    <description>500 mg iron isomaltoside 1000 given as a bolus injection over 2 minutes</description>
    <arm_group_label>500 mg iron isomaltoside 1000 as bolus injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1000 mg iron isomaltoside 1000</intervention_name>
    <description>1000 mg iron isomaltoside 1000 given as a infusion over 15 minutes</description>
    <arm_group_label>1000 mg iron isomaltoside 1000 as intravenous infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women, aged more than 18 years.&#xD;
&#xD;
          2. Weight above 50 kg.&#xD;
&#xD;
          3. Subjects diagnosed with non-hematological malignancies (solid tumors only) receiving&#xD;
             chemotherapy at least 1 day prior to screening and who are going to receive at least&#xD;
             two more chemotherapy cycles.&#xD;
&#xD;
          4. Hb &lt; 12 g/dL.&#xD;
&#xD;
          5. TfS &lt;50%.&#xD;
&#xD;
          6. Serum Ferritin &lt;800 ng/ml.&#xD;
&#xD;
          7. An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.&#xD;
&#xD;
          8. Willingness to participate after informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Anaemia caused primarily by other factors than CIA.&#xD;
&#xD;
          2. IV or oral iron treatment within 4 weeks prior to screening visit.&#xD;
&#xD;
          3. Erythrypoietin treatment within 4 weeks prior to screening visit.&#xD;
&#xD;
          4. Blood transfusion within 4 weeks prior to screening visit.&#xD;
&#xD;
          5. Imminent expectation of blood transfusion on part of treating physician.&#xD;
&#xD;
          6. Iron overload or disturbances in utilization of iron (e.g. haemochromatosis and&#xD;
             haemosiderosis).&#xD;
&#xD;
          7. Drug hypersensitivity (i.e. previous hypersensitivity to Iron Dextran or iron mono- or&#xD;
             disaccharide complexes or to iron sulfate).&#xD;
&#xD;
          8. Known hypersensitivity to any excipients in the investigational drug products.&#xD;
&#xD;
          9. Subjects with a history of multiple allergies.&#xD;
&#xD;
         10. Decompensated liver cirrhosis and hepatitis (alanine aminotransferase (ALAT) &gt; 3 times&#xD;
             upper normal limit).&#xD;
&#xD;
         11. History of Immunocompromise and/or history of Hepatitis B and/or C.&#xD;
&#xD;
         12. Active acute or chronic infections (assessed by clinical judgement and if deemed&#xD;
             necessary by investigator supplied with white blood cells (WBC) and C-reactive protein&#xD;
             (CRP)).&#xD;
&#xD;
         13. Rheumatoid arthritis with symptoms or signs of active joint inflammation.&#xD;
&#xD;
         14. Pregnancy and nursing (To avoid pregnancy, women have to be postmenopausal (at least&#xD;
             12 months must have elapsed since last menstruation), surgically sterile, or women of&#xD;
             child bearing potential must use one of the following contraceptives during the whole&#xD;
             study period and after the study has ended for at least 5 times plasma biological&#xD;
             half-life (5 days) of the investigational medicinal product: Contraceptive pills,&#xD;
             intrauterine devices (IUD), contraceptive depot injections (prolonged-release&#xD;
             gestagen), subdermal implantation, vaginal ring, and transdermal patches).&#xD;
&#xD;
         15. Planned elective surgery during the study.&#xD;
&#xD;
         16. Participation in any other clinical study (except chemotherapy protocol) within 3&#xD;
             months prior to screening.&#xD;
&#xD;
         17. Known intolerance to oral iron treatment.&#xD;
&#xD;
         18. Untreated B12 or folate deficiency.&#xD;
&#xD;
         19. Any other medical condition that, in the opinion of Principal Investigator, may cause&#xD;
             the subject to be unsuitable for the completion of the study or place the subject at&#xD;
             potential risk from being in the study. Example, Uncontrolled Hypertension, Unstable&#xD;
             Ischemic Heart Disease or Uncontrolled Diabetes Mellitus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>India</country>
  </removed_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>October 1, 2010</study_first_submitted>
  <study_first_submitted_qc>October 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2010</study_first_posted>
  <last_update_submitted>June 26, 2013</last_update_submitted>
  <last_update_submitted_qc>June 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Iron isomaltoside 1000</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

